iconstar paper   HIV Articles  
Back grey arrow rt.gif
 
 
PrEP & Lipids, Weight Gain
 
 
  From these PrEP trials of TAF & cabotegravir we do not see lipids increases. We do see lipidsincreases after switch from TDF to TAF.
 
CROI 2019: CABOTEGRAVIR IS NOT ASSOCIATED WITH WEIGHT GAIN IN HIV-NEGATIVE INDIVIDUALS - (03/06/19)
 

0508201

CROI: Results from a PrEP Demonstration Project for At-Risk Cisgender Women in the US - PrEP/PEP at CROI - (04/04/20)
 
DRUG LEVELS, ADHERENCE, AND RISKS FOR LOW ADHERENCE IN THE DISCOVER PrEP STUDY (03/13/20)
 
IMPACT OF PrEP AND TasP ON INCIDENCE OF HIV DIAGNOSES IN 48 HIGHEST-BURDEN US AREAS - (03/16/20)
 
FTC/TAF + BIC Postexposure Prophylaxis Protects Macaques Against Rectal SHIV Infection - (03/11/20)
 
IAS 2019: DISCOVER STUDY for HIV Pre-Exposure Prophylaxis: F/TAF has a more Rapid Onset and Longer Sustained Duration of HIV Protection Compared with F/TDF - (07/25/19)
 

0508202

Longer Term Efficacy and Safety of F/TAF and F/TDF For HIV PrEP: DISCOVER Trial Week 96 Results - (03/11/20)
 

0508203

DISCOVER: 96-Week Follow-up of Black and Hispanic/Latinx Study Participants - (03/11/20)
 

0508204

  
 
 
 
  iconpaperstack View Older Articles   Back to Top   www.natap.org